SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012 on October 3 in Quebec City.
News | 08. 14. 2012
Art Pappas joins a Venture Capital Panel at BioContactQuébec 2012 on October 3 in Quebec City.
